QUETHERA
Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.
QUETHERA
Industry:
Biopharma Biotechnology Genetics Pharmaceutical
Founded:
2013-01-01
Address:
Babraham, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.quethera.co.uk
Total Employee:
1+
Status:
Active
Contact:
+44 (0) 1223 804059
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
IPv6 Pound Sterling 1and1 1and1 Email Solutions
Current Employees Featured
Founder
Investors List
Wellcome Trust
Wellcome Trust investment in Grant - Quethera
Parkwalk Advisors
Parkwalk Advisors investment in Seed Round - Quethera
University of Cambridge Enterprise
University of Cambridge Enterprise investment in Seed Round - Quethera
Future Planet Capital
Future Planet Capital investment in Seed Round - Quethera
UK Innovation & Science Seed Fund
UK Innovation & Science Seed Fund investment in Seed Round - Quethera
More informations about "Quethera"
News | Astellas Pharma Inc.
Aug 10, 2018 TOKYO, CAMBRIDGE (UK), August 10, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter …See details»
Quethera - Crunchbase Company Profile & Funding
Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual …See details»
Quethera: a new vision for saving glaucoma patients’ eyesight
Astellas buys eye gene therapy biotech Quethera for …
6 days ago Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on …See details»
Astellas Pharma US | Quethera Acquisition | News Releases
Aug 10, 2018 TOKYO and CAMBRIDGE, England, Aug. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., "Astellas") and Quethera …See details»
Quethera 2025 Company Profile: Valuation, Investors
Quethera General Information Description. Developer of gene therapy technologies designed to improve the treatment of common blinding eye diseases. The company's technology focuses on the development of therapies …See details»
Astellas announces acquisition of Cambridge spin-out Quethera
Aug 10, 2018 Astellas Pharma Inc. and Quethera Limited today announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is …See details»
QUETHERA LIMITED Company Profile - Dun & Bradstreet
Quethera limited. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united kingdom / cambridge …See details»
QUETHERA LIMITED overview - Find and update company …
People for QUETHERA LIMITED (08450540) More for QUETHERA LIMITED (08450540) Registered office address 300 Dashwood Lang Road, Bourne Business Park, Addlestone, …See details»
Quethera - VentureRadar
Quethera is a gene therapy company developing a novel treatment for glaucoma. The company targeted delivering gene products for neuroprotectants and their receptors directly to the eye. …See details»
Quethera - Contacts, Employees, Board Members, Advisors & Alumni
Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases.See details»
Quethera announces financing for gene therapy to prevent …
Sep 17, 2015 Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven’s Rainbow Seed …See details»
A Fork in the Road: Quethera’s Story – UKI2S
Oct 23, 2018 As a marathon Series A funding round loomed, Quethera reached a fork in the road. Peter, a veteran of major pharma companies including Pfizer, AstraZeneca and OSI …See details»
Astellas Announces Acquisition of Quethera - BioSpace
Aug 10, 2018 Quethera Limited, based at the Babraham Research Campus in Cambridge, United Kingdom, is a gene therapy company dedicated to improving the future treatment of …See details»
Quethera - Funding, Financials, Valuation & Investors - Crunchbase
Mar 1, 2018 Quethera has raised 4 rounds. Their latest funding was raised on Mar 1, 2018 from a Convertible Note round. Quethera is funded by 5 investors. Future Planet Capital and Future …See details»
Astellas absorbs U.K. ocular gene therapy player Quethera
Aug 10, 2018 Japan’s Astellas Pharma has delved deeper into the gene therapy sector, picking up U.K. specialist Quethera for around $109 million. The £85 million deal—split into upfront …See details»
Gene Therapy Company Quethera Obtains Grant From Wellcome …
Mar 4, 2016 Quethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in Cambridge, has obtained a grant from the Wellcome Trust Pathfinder …See details»
Astellas Announces Acquisition Of Quethera To Enhance Focus On ...
Aug 10, 2018 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., "Astellas") and Quethera Limited (CEO: Peter Widdowson, Ph.D., "Quethera") today …See details»
Quethera: A new vision for gene therapy – Cambridge Enterprise
Sep 21, 2015 Quethera, with its targeting of glaucoma, is different in two ways. Glaucoma isn’t a genetic disease. There are genetic factors involved (familial history is quite well-documented), …See details»
Quethera – Funding, Valuation, Investors, News
Aug 13, 2018 TOKYO, CAMBRIDGE (UK), August 10, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter …See details»